| Identification | Back Directory | [Name]
H-LEU-SER-LYS-LEU-NH2 | [CAS]
283609-79-0 | [Synonyms]
LSKL
LSKL(a)
LSKL, BR
LSKL-NH2
LEU-SER-LYS-LEU-NH2
H-LEU-SER-LYS-LEU-NH2
H-Leu-Ser-Lys-Leu-NH?
Leu-Ser-Lys-Leu peptide
INHIBITOR OF THROMBOSPONDIN (TSP-1)
L-Leucinamide, L-leucyl-L-seryl-L-lysyl-
H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate salt
(S)-6-amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((S)-2-((S)-2-amino-4-methylpentanamido)-3-hydroxypropanamido)hexanamide | [Molecular Formula]
C21H42N6O5 | [MDL Number]
MFCD03093441 | [MOL File]
283609-79-0.mol | [Molecular Weight]
458.6 |
| Chemical Properties | Back Directory | [Boiling point ]
817.8±65.0 °C(Predicted) | [density ]
1.143±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMSO : ≥ 100 mg/mL (218.05 mM) | [form ]
Solid | [pka]
13.40±0.46(Predicted) | [color ]
White to off-white | [Sequence]
H-Leu-Ser-Lys-Leu-NH2 |
| Hazard Information | Back Directory | [Uses]
L-Leucyl-L-seryl-L-lysyl-L-leucinamide can be useful in the study of relative contributions of core protein and solvation shell in terahertz dielectric properties of protein solutions. | [in vivo]
LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling[1].
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy[3]. | Animal Model: | 103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.
|
| [storage]
Store at -20°C |
|
|